Asthma is a chronic debilitating inflammatory disease of the lungs whose incidence is on the rise especially among minority groups. Asthma is especially important during childhood when it accounts for the most common reason for a child's visit to the emergency room and hospitalization. Our goal is to provide the basis for developing novel therapeutic approaches for the treatment of asthma and other allergic disorders by elucidating mechanisms of peripheral blood and tissue eosinophilia. This application is based on the hypothesis that eosinophilic airway inflammation (characteristic of asthma) is mediated in part by eotaxin, a CC chemokine that specifically recruits and activates gene expression in eosinophils. Unlike all other eosinophil chemoattractants that have been extensively characterized, eotaxin is eosinophil specific. Using eotaxin deficient mice, this application will test the hypothesis that eotaxin plays a role in the pathogenesis of antigen-induced eosinophilic inflammation. Using mice that over-express eotaxin in combination with other eosinophil activating cytokines, the consequences of chronic eotaxin over-production will be examined. We will also test the hypothesis that recruited tissue eosinophils express unique gene products, some of which contribute to the inflammatory process and others which may provide markers for tissue eosinophils. The proposed studies will provide a scientific basis for the design of agents that target eotaxin. They will also identify gene products specifically expressed in eosinophils that have been recruited into the inflamed lung. These gene products will provide future targets for therapeutic intervention and add novel insight into the poorly understood function of eosinophils.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI042242-01
Application #
2451731
Study Section
Lung Biology and Pathology Study Section (LBPA)
Project Start
1998-02-01
Project End
2003-01-31
Budget Start
1998-02-01
Budget End
1999-01-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Simon, Dagmar; Wardlaw, Andrew; Rothenberg, Marc E (2010) Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol 126:3-13; quiz 14-5
Zuo, Li; Fulkerson, Patricia C; Finkelman, Fred D et al. (2010) IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway. J Immunol 185:660-9
Miyazaki, Dai; Nakamura, Takao; Ohbayashi, Masaharu et al. (2009) Ablation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1/CCR3 blockade. Int Immunol 21:187-201
Blanchard, Carine; Rothenberg, Marc E (2008) Basic pathogenesis of eosinophilic esophagitis. Gastrointest Endosc Clin N Am 18:133-43;x
Brandt, Eric B; Mingler, Melissa K; Stevenson, Michelle D et al. (2008) Surfactant protein D alters allergic lung responses in mice and human subjects. J Allergy Clin Immunol 121:1140-1147.e2
Mishra, Anil; Wang, Meiqin; Schlotman, James et al. (2007) Resistin-like molecule-beta is an allergen-induced cytokine with inflammatory and remodeling activity in the murine lung. Am J Physiol Lung Cell Mol Physiol 293:L305-13
Munitz, Ariel; Bachelet, Ido; Finkelman, Fred D et al. (2007) CD48 is critically involved in allergic eosinophilic airway inflammation. Am J Respir Crit Care Med 175:911-8
Nikolaidis, Nikolaos M; Wang, Timothy C; Hogan, Simon P et al. (2006) Allergen induced TFF2 is expressed by mucus-producing airway epithelial cells but is not a major regulator of inflammatory responses in the murine lung. Exp Lung Res 32:483-97
Fulkerson, Patricia C; Fischetti, Christine A; Hassman, Lynn M et al. (2006) Persistent effects induced by IL-13 in the lung. Am J Respir Cell Mol Biol 35:337-46
Zimmermann, Nives; Rothenberg, Marc E (2006) The arginine-arginase balance in asthma and lung inflammation. Eur J Pharmacol 533:253-62

Showing the most recent 10 out of 53 publications